BSI 093
Alternative Names: BSI-093Latest Information Update: 26 Mar 2024
At a glance
- Originator Biosion
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Butyrophilin modulators; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 05 Mar 2024 BSI 093 is available for licensing as of 05 Mar 2024. https://www.biosion.com/partnership
- 05 Mar 2024 Preclinical trials in Solid tumours in China (Parenteral) prior to February 2024 (Biosion pipeline, February 2024)
- 05 Mar 2024 Pharmacodynamics data from a preclinical studies in Solid tumor released by Biosion (Biosion pipeline February 2024)